Confined or spread disease-Confined only to the breast Posts on Medivizor
Navigation Menu

Confined or spread disease-Confined only to the breast Posts on Medivizor

Improving the tolerability of neratinib in patients with early-stage HER2-positive breast cancer.

Improving the tolerability of neratinib in patients with early-stage HER2-positive breast cancer.

Posted by on Aug 15, 2020 in Breast cancer | 0 comments

In a nutshell This trial evaluated strategies to improve diarrhea as a side effect of neratinib (Nerlynx) treatment in patients with HER2-positive breast cancer (BC). The authors showed that slowly increasing the doses of neratinib or taking anti-diarrhea medication can improve this side effect. Some background Neratinib (Nerlynx) is a targeted...

Read More

Long term effects of hypofractionated prone intensity-modulated radiation therapy after breast conservation surgery in patients with breast cancer

Long term effects of hypofractionated prone intensity-modulated radiation therapy after breast conservation surgery in patients with breast cancer

Posted by on Jul 12, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated long-term outcomes of combining hypofractionated intensity-modulated radiation therapy (H-IMRT) with prone-positioning in patients after conservation surgery for breast cancer. The authors found that this combination safely controlled cancer locally without affecting regional lymph nodes. Some background Adjuvant...

Read More

The effects of cholesterol-lowering drugs on breast cancer relapse in postmenopausal women under aromatase inhibitor treatment

The effects of cholesterol-lowering drugs on breast cancer relapse in postmenopausal women under aromatase inhibitor treatment

Posted by on Jul 5, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated the link between statin (cholesterol-lowering drugs) use and risks of breast cancer (BC) relapse under adjuvant aromatase inhibitors (AI) therapy in women after their menopause. The main finding was that statin use was related with lower risks of BC relapse in such patients. Some background Women with...

Read More

How effective is hormonal therapy for patients with hormone receptor positive early breast cancer?

Posted by on Apr 25, 2020 in Breast cancer | 0 comments

In a nutshell This study examined the effectiveness of hormonal therapy in premenopausal women with hormone receptor-positive early breast cancer with or without other treatments. The authors concluded that patients who received hormonal therapy had a higher chance of survival and without a return of cancer. Some background The hormone...

Read More

Searching for patients with early breast cancer to trial a partial-radiation treatment

Posted by on Oct 24, 2019 in Breast cancer | 0 comments

In a nutshell This trial aims to find out what dose of radiation therapy is effective in the shortest time period for women with newly diagnosed breast cancer, or ductal carcinoma in-situ (DCIS). The main outcome that will be measured is if patients experience any side effects. The study is taking place in New Jersey and New York, the United States. The...

Read More

Radiotherapy during surgery in early breast cancer – what is the risk of tumor recurrence?

Posted by on May 26, 2019 in Breast cancer | 0 comments

In a nutshell This study investigated the safety and effectiveness of intraoperative radiotherapy (IORT; radiotherapy during surgery) in early breast cancer (BC). They found that tumor recurrence was low after IORT. Some background Early breast cancer (BC) can be treated using different approaches. Most patients undergo breast-conserving therapy...

Read More

Looking for patients with estrogen receptor-positive breast cancer to test a new treatment combination

Posted by on May 11, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will evaluate the safety and effectiveness of ribociclib (Kisqali) combined with hormonal therapy in patients with estrogen receptor-positive (ER+) breast cancer (BC). The main outcome will be the number of patients that complete 1 year of treatment and survival without signs of cancer. The trial will...

Read More

Denosumab treatment in HR+ breast cancer

Posted by on Apr 30, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if adding the medication denosumab (Prolia, Xgeva) to cancer treatment for women with breast cancer reduces the risk of bone fractures. The study found that the patients treated with denosumab survived better, but there was no significant difference in the number of bone fractures. Some background Breast...

Read More

Searching for patients with early-stage HER2+ breast cancer to trial a new treatment regime

Posted by on Apr 24, 2019 in Breast cancer | 0 comments

In a nutshell This study will examine how safe and effective the medication atezolizumab (Tecentriq) is in combination with other anti-cancer medicines for treating early stage HER2+ breast cancer. The main outcome that will be measured is how many patients completely respond to treatment, with no trace of the cancer remaining. The details...

Read More

Searching for patients with triple negative breast cancer to test a new medication

Posted by on Apr 22, 2019 in Breast cancer | 0 comments

In a nutshell This phase 3 trial will investigate the safety and effectiveness of adagloxad simolenin (AGS)/OBI-821 in triple-negative breast cancer (TNBC). The main outcome will be a change in survival without invasive disease. The details Breast cancer (BC) is one of the most common cancers. BC treatment depends on the tumor type....

Read More